Ocular Therapeutix plans Q4 FDA filing for AXPAXLI after SOL-1 trial win
Ocular Therapeutix reported that its SOL-1 trial beat an approved anti‑VEGF therapy on a primary endpoint, achieving a p‑value below 0.0006. The company said the FDA has agreed to a single‑trial 505(b)(2) submission path and is targeting an NDA filing in Q4 2024. Management noted the firm holds roughly $600 million in cash as of June 30, giving it runway into 2028, though full commercialization costs are not yet accounted for. The top‑line data timeline was shifted to the first quarter of 2028 after an amendment to add a secondary endpoint.
Why it matters
The planned Q4 filing could move the product toward market approval, creating a potential revenue catalyst for OCUL. The strong cash position and runway support the company’s ability to fund the filing and any launch activities without immediate dilution.
Key facts
- 1SOL-1 achieved superiority over aflibercept with a p‑value of less than 0.0006. investing.com
- 2The FDA supports a single‑trial 505(b)(2) submission based on SOL-1 and confirmatory evidence. investing.com
- 3Ocular Therapeutix had about $600 million in cash as of June 30. investing.com
- 4The cash runway extends into 2028, excluding full commercialization costs. investing.com
- 5The company targets an NDA submission in Q4 2024. investing.com
- 6Amending SOL-1 moved topline data timing to Q1 2028 from Q1 2027. finance.yahoo.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.